258 related articles for article (PubMed ID: 21697355)
1. Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model.
van Giezen JJ; Sidaway J; Glaves P; Kirk I; Björkman JA
J Cardiovasc Pharmacol Ther; 2012 Jun; 17(2):164-72. PubMed ID: 21697355
[TBL] [Abstract][Full Text] [Related]
2. Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans.
Wittfeldt A; Emanuelsson H; Brandrup-Wognsen G; van Giezen JJ; Jonasson J; Nylander S; Gan LM
J Am Coll Cardiol; 2013 Feb; 61(7):723-7. PubMed ID: 23312702
[TBL] [Abstract][Full Text] [Related]
3. Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model.
Wang K; Zhou X; Huang Y; Khalil M; Wiktor D; van Giezen JJ; Penn MS
Thromb Haemost; 2010 Sep; 104(3):609-17. PubMed ID: 20694285
[TBL] [Abstract][Full Text] [Related]
4. Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy).
Storey RF; Becker RC; Harrington RA; Husted S; James SK; Cools F; Steg PG; Khurmi NS; Emanuelsson H; Lim ST; Cannon CP; Katus HA; Wallentin L
Am J Cardiol; 2011 Dec; 108(11):1542-6. PubMed ID: 21890085
[TBL] [Abstract][Full Text] [Related]
5. Ticagrelor induces adenosine triphosphate release from human red blood cells.
Ohman J; Kudira R; Albinsson S; Olde B; Erlinge D
Biochem Biophys Res Commun; 2012 Feb; 418(4):754-8. PubMed ID: 22306816
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1.
Armstrong D; Summers C; Ewart L; Nylander S; Sidaway JE; van Giezen JJ
J Cardiovasc Pharmacol Ther; 2014 Mar; 19(2):209-19. PubMed ID: 24414167
[TBL] [Abstract][Full Text] [Related]
7. Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome.
Bonello L; Laine M; Kipson N; Mancini J; Helal O; Fromonot J; Gariboldi V; Condo J; Thuny F; Frere C; Camoin-Jau L; Paganelli F; Dignat-George F; Guieu R
J Am Coll Cardiol; 2014 Mar; 63(9):872-7. PubMed ID: 24291273
[TBL] [Abstract][Full Text] [Related]
8. Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism.
Nylander S; Femia EA; Scavone M; Berntsson P; Asztély AK; Nelander K; Löfgren L; Nilsson RG; Cattaneo M
J Thromb Haemost; 2013 Oct; 11(10):1867-76. PubMed ID: 23890048
[TBL] [Abstract][Full Text] [Related]
9. Effects of N-nitro-L-arginine on coronary artery tone and reactive hyperemia after brief coronary occlusion in conscious dogs.
Muramatsu K; Numaguchi K; Egashira K; Takahashi T; Kasuya H; Takeshita A
Coron Artery Dis; 1994 Oct; 5(10):815-20. PubMed ID: 7866601
[TBL] [Abstract][Full Text] [Related]
10. Comparison of ticagrelor and thienopyridine P2Y(12) binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis.
van Giezen JJ; Berntsson P; Zachrisson H; Björkman JA
Thromb Res; 2009 Nov; 124(5):565-71. PubMed ID: 19692114
[TBL] [Abstract][Full Text] [Related]
11. Ticagrelor, but not clopidogrel and prasugrel, prevents ADP-induced vascular smooth muscle cell contraction: a placebo-controlled study in rats.
Grzesk G; Kozinski M; Navarese EP; Krzyzanowski M; Grzesk E; Kubica A; Siller-Matula JM; Castriota F; Kubica J
Thromb Res; 2012 Jul; 130(1):65-9. PubMed ID: 22265722
[TBL] [Abstract][Full Text] [Related]
12. Role of newly formed platelets in thrombus formation in rat after clopidogrel treatment: comparison to the reversible binding P2Y₁₂ antagonist ticagrelor.
Kuijpers MJ; Megens RT; Nikookhesal E; Feijge MA; De Mey JG; oude Egbrink MG; van Giezen JJ; Heemskerk JW
Thromb Haemost; 2011 Dec; 106(6):1179-88. PubMed ID: 22071958
[TBL] [Abstract][Full Text] [Related]
13. Adenosine-mediated inhibition of platelet aggregation by acadesine. A novel antithrombotic mechanism in vitro and in vivo.
Bullough DA; Zhang C; Montag A; Mullane KM; Young MA
J Clin Invest; 1994 Oct; 94(4):1524-32. PubMed ID: 7929829
[TBL] [Abstract][Full Text] [Related]
14. Effects of drugs and sympathetic nerve stimuation on retrograde coronary blood flow in dogs with experimental coronary occlusion.
Takenaka F; Matuo M; Ishihara T
Arch Int Pharmacodyn Ther; 1975 Mar; 214(1):75-85. PubMed ID: 239650
[TBL] [Abstract][Full Text] [Related]
15. Ticagrelor: from discovery to Phase III clinical trial.
Siller-Matula JM; Jilma B
Future Cardiol; 2010 Nov; 6(6):753-64. PubMed ID: 21142630
[TBL] [Abstract][Full Text] [Related]
16. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
James S; Akerblom A; Cannon CP; Emanuelsson H; Husted S; Katus H; Skene A; Steg PG; Storey RF; Harrington R; Becker R; Wallentin L
Am Heart J; 2009 Apr; 157(4):599-605. PubMed ID: 19332184
[TBL] [Abstract][Full Text] [Related]
17. Differences in vasodilatory response to dipyridamole between patients with angina and normal coronary arteries and patients with successful coronary angioplasty.
Finocchiaro ML; Buffon A; Beltrame JF; Lupi A; Conti E; Lanza GA; Cianflone D; Crea F; Maseri A
Coron Artery Dis; 1995 Jun; 6(6):479-87. PubMed ID: 7551269
[TBL] [Abstract][Full Text] [Related]
18. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial.
Held C; Asenblad N; Bassand JP; Becker RC; Cannon CP; Claeys MJ; Harrington RA; Horrow J; Husted S; James SK; Mahaffey KW; Nicolau JC; Scirica BM; Storey RF; Vintila M; Ycas J; Wallentin L
J Am Coll Cardiol; 2011 Feb; 57(6):672-84. PubMed ID: 21194870
[TBL] [Abstract][Full Text] [Related]
19. P2Y₁₂ receptor inhibitors: integrating ticagrelor into the management of acute coronary syndrome.
Crouch MA; Colucci VJ; Howard PA; Spinler SA
Ann Pharmacother; 2011 Sep; 45(9):1151-6. PubMed ID: 21852599
[TBL] [Abstract][Full Text] [Related]
20. Novel antiplatelet agent ticagrelor in the management of acute coronary syndrome.
Ramaraj R; Movahed MR; Hashemzadeh M
J Interv Cardiol; 2011 Jun; 24(3):199-207. PubMed ID: 21198849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
